Senthil Selvaraj1, Brian Claggett2, Sanjiv J Shah3, Inder S Anand4, Jean L Rouleau5, Akshay S Desai2, Eldrin F Lewis2, Muthiah Vaduganathan2, Stephen Y Wang2, Bertram Pitt6, Nancy K Sweitzer7, Marc A Pfeffer2, Scott D Solomon2. 1. Division of Cardiology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia (S.S.). 2. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (B.C., A.S.D., E.F.L., M.V., S.Y.W., M.A.P., S.D.S.). 3. The Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.). 4. VA Medical Center, University of Minnesota, Minneapolis (I.S.A). 5. Department of Medicine, Montreal Heart Institute, University of Montreal, QC, Canada (J.L.R.). 6. Division of Cardiology, Department of Medicine, University of Michigan School of Medicine, Ann Arbor (B.P.). 7. The Sarver Heart Center, University of Arizona College of Medicine, Tucson (N.K.S.).
Abstract
BACKGROUND: The prognostic value of physical examination, its relation to quality of life, and influence of therapy in heart failure with preserved ejection fraction is not well known. METHODS AND RESULTS: We studied participants from the Americas with available physical examination (jugular venous distention, rales, and edema) at baseline in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist). The association of the number of signs of congestion with the primary outcome (cardiovascular death or heart failure hospitalization), its individual components, and all-cause mortality was assessed using time-updated, multivariable-adjusted Cox regression analyses. We evaluated whether spironolactone improved congestion at 4 months and whether improvement in congestion was related to quality of life as assessed by Kansas City Cardiomyopathy Questionnaire overall summary scores and to outcomes. Among 1644 participants, 22%, 54%, 20%, and 4% had 0, 1, 2, and 3 signs of congestion, respectively, at baseline. After multivariable adjustment, each additional increase in sign of congestion was associated with a 30% to 60% increased risk of each outcome ( P<0.001). Spironolactone reduced the total number of signs of congestion by -0.10 ( P=0.005) signs, jugular venous distention (odds ratio, 0.60; P=0.01), and edema (odds ratio, 0.74; P=0.006) at 4 months compared with placebo. Each reduction in sign of congestion was independently associated with a 4.0 (95% CI, 2.4-5.6) point improvement in Kansas City Cardiomyopathy Questionnaire overall summary score. When assessed simultaneously, time-updated, but not baseline congestion, predicted outcomes. CONCLUSIONS: In heart failure with preserved ejection fraction, the physical exam provides independent prognostic value for adverse outcomes. Spironolactone improved congestion compared with placebo. Reducing congestion was independently associated with improved quality of life and outcomes and is a modifiable risk factor. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00094302.
BACKGROUND: The prognostic value of physical examination, its relation to quality of life, and influence of therapy in heart failure with preserved ejection fraction is not well known. METHODS AND RESULTS: We studied participants from the Americas with available physical examination (jugular venous distention, rales, and edema) at baseline in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist). The association of the number of signs of congestion with the primary outcome (cardiovascular death or heart failure hospitalization), its individual components, and all-cause mortality was assessed using time-updated, multivariable-adjusted Cox regression analyses. We evaluated whether spironolactone improved congestion at 4 months and whether improvement in congestion was related to quality of life as assessed by Kansas City Cardiomyopathy Questionnaire overall summary scores and to outcomes. Among 1644 participants, 22%, 54%, 20%, and 4% had 0, 1, 2, and 3 signs of congestion, respectively, at baseline. After multivariable adjustment, each additional increase in sign of congestion was associated with a 30% to 60% increased risk of each outcome ( P<0.001). Spironolactone reduced the total number of signs of congestion by -0.10 ( P=0.005) signs, jugular venous distention (odds ratio, 0.60; P=0.01), and edema (odds ratio, 0.74; P=0.006) at 4 months compared with placebo. Each reduction in sign of congestion was independently associated with a 4.0 (95% CI, 2.4-5.6) point improvement in Kansas City Cardiomyopathy Questionnaire overall summary score. When assessed simultaneously, time-updated, but not baseline congestion, predicted outcomes. CONCLUSIONS: In heart failure with preserved ejection fraction, the physical exam provides independent prognostic value for adverse outcomes. Spironolactone improved congestion compared with placebo. Reducing congestion was independently associated with improved quality of life and outcomes and is a modifiable risk factor. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00094302.
Authors: Theophilus E Owan; David O Hodge; Regina M Herges; Steven J Jacobsen; Veronique L Roger; Margaret M Redfield Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: Mark H Drazner; Anne S Hellkamp; Carl V Leier; Monica R Shah; Leslie W Miller; Stuart D Russell; James B Young; Robert M Califf; Anju Nohria Journal: Circ Heart Fail Date: 2008-09 Impact factor: 8.790
Authors: Anju Nohria; Sui W Tsang; James C Fang; Eldrin F Lewis; John A Jarcho; Gilbert H Mudge; Lynne W Stevenson Journal: J Am Coll Cardiol Date: 2003-05-21 Impact factor: 24.094
Authors: Muthiah Vaduganathan; Brian L Claggett; Akshay S Desai; Stefan D Anker; Sergio V Perrone; Stefan Janssens; Davor Milicic; Juan L Arango; Milton Packer; Victor C Shi; Martin P Lefkowitz; John J V McMurray; Scott D Solomon Journal: J Am Coll Cardiol Date: 2019-11-11 Impact factor: 24.094
Authors: Senthil Selvaraj; Peder L Myhre; Muthiah Vaduganathan; Brian L Claggett; Kunihiro Matsushita; Dalane W Kitzman; Barry A Borlaug; Amil M Shah; Scott D Solomon Journal: JACC Heart Fail Date: 2020-06-10 Impact factor: 12.035